Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Frontera Therapeutics Begins Trials for Three Leading Gene Therapy Candidates

publication date: Feb 17, 2023

Frontera Therapeutics, a US-China gene therapy company, has begun China trials of its three leading candidates – all starting in the first two months of 2023. The company’s APEX Technology & Manufacturing Platform is an adeno-associated virus (AAV) gene expression system based on novel and clinically validated AAV vectors. The trials include FT-002 for X-linked retinitis pigmentosa (XLRP); FT-003 for neovascular or wet age-related macular degeneration (wAMD); and FT-001 for Leber Congenital Amaurosis-2, an inherited retinal disease. Frontera is headquartered in the Boston area with labs and a manufacturing facility in Suzhou. More details....

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital